Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | PDE1A | P54750 | 1/20 | 0.63 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.63 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirodenafil SCHEMBL29611578 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3APDE1APDE1B | |
| Mirodenafil SCHEMBL22028340 | 0.99 | PDE5A (0.99) | PDE5APDE3BPDE3APDE1APDE1B | |
| Mirodenafil SCHEMBL29409452 | 0.99 | PDE5A (0.99) | PDE5APDE3BPDE3APDE1APDE1B | |
| Mirodenafil SCHEMBL7048752 | 0.99 | PDE5A (0.97) | PDE5APDE3BPDE3APDE1APDE1B | |
| Mirodenafil SCHEMBL7048756 | 0.97 | PDE5A (0.94) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL24307701 | 0.96 | PDE5A (0.92) | PDE5APDE3BPDE3A | |
| SCHEMBL6475482 | 0.95 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL13557093 | 0.95 | PDE5A (0.90) | PDE5A | |
| SCHEMBL6475614 | 0.94 | PDE5A (0.88) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6483207 | 0.93 | PDE5A (0.88) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741012-A2 | COMPOSITIONS AND METHODS FOR REDUCING AMYLOID BETA FORMATION AND COMPOSITION THEREFORE | Aribio Co., Ltd. (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026088136-A1 | METHODS OF TREATING A NEURODEGENERATIVE DISEASE | ARIBIO CO., LTD. (KR) | 2026-04-30 | — | — | WO | claimed |
| EP-4327813-B1 | COADMINISTRATION OF MIRODENAFIL WITH CORT-108297 FOR PREVENTING AND TREATING DEMENTIA | ARIBIO CO LTD (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4687904-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH MITOCHONDRIAL COMPLEX IV DEFICIENCY | Charité - Universitätsmedizin Berlin (DE) | 2026-02-11 | — | — | EP | claimed |
| US-20260021100-A1 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | ARIBIO CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| EP-4656194-A1 | COMPOSITION FOR PREVENTING OR TREATING POST-TRAUMATIC STRESS DISORDER, COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR AS ACTIVE INGREDIENT | Aribio Co., Ltd (KR) | 2025-12-03 | — | — | EP | claimed |
| US-12485124-B2 | Methods for treating alzheimer disease and for reducing amyloid beta formation | ARIBIO CO., LTD. (KR) | 2025-12-02 | — | — | US | claimed |
| WO-2025134069-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025134070-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO., LTD. (KR) | 2025-06-26 | — | — | WO | claimed |
| US-20250205239-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | ARIBIO CO LTD (KR) | 2025-06-26 | — | — | US | claimed |
| EP-3723737-B1 | POROUS SILICA PARTICLES FOR USE IN COMPRESSED PHARMACEUTICAL DOSAGE FORM | NANOLOGICA AB (SE) | 2022-05-18 | — | — | EP | claimed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| EP-3946351-A2 | COMPOSITIONS AND METHODS FOR REDUCING AMYLOID BETA FORMATION ON AND COMPOSITION THEREFORE | Aribio Co., Ltd. (KR) | 2022-02-09 | — | — | EP | claimed |
| US-11241485-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | claimed |
| US-9271916-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | claimed |
| US-20140187775-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-07-03 | — | — | US | claimed |
| WO-2013036081-A2 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-03-14 | — | — | WO | claimed |
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | claimed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | claimed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | PDE5A 686/4885PDE3B 601/4885PDE3A 734/4885 |
| US-20260021100-A1 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | BACE1, BACE2, WNT3A | PDE5A 40/4885PDE3B 37/4885PDE3A 31/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | PDE5A 39/4885PDE3B 14/4885PDE3A 7/4885 |
| US-20140187775-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE3B 2/4885PDE3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.